DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412.
about
c-MYC Generates Repair Errors via Increased Transcription of Alternative-NHEJ Factors, LIG3 and PARP1, in Tyrosine Kinase-Activated LeukemiasFLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitationsOverexpression of MN1 confers resistance to chemotherapy, accelerates leukemia onset, and suppresses p53 and Bim inductionTargeting of CD34+CD38- cells using Gemtuzumab ozogamicin (Mylotarg) in combination with tipifarnib (Zarnestra) in Acute Myeloid Leukaemia.Cells expressing FLT3/ITD mutations exhibit elevated repair errors generated through alternative NHEJ pathways: implications for genomic instability and therapy.Acute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t(8;21) transcripts.Flt3-ITD alters chemotherapy response in vitro and in vivo in a p53-dependent manner.Suberoylanilide hydroxamic acid induces hypersensitivity to radiation therapy in acute myelogenous leukemia cells expressing constitutively active FLT3 mutants.Ebf1 heterozygosity results in increased DNA damage in pro-B cells and their synergistic transformation by Pax5 haploinsufficiencyPre-apoptotic response to therapeutic DNA damage involves protein modulation of Mcl-1, Hdm2 and Flt3 in acute myeloid leukemia cells.Molecular mechanisms of drug resistance in acute myeloid leukaemia.Clinical relevance of the homologous recombination machinery in cancer therapy.Synthetic lethal targeting of DNA double-strand break repair deficient cells by human apurinic/apyrimidinic endonuclease inhibitors.HDAC Inhibition Induces MicroRNA-182, which Targets RAD51 and Impairs HR Repair to Sensitize Cells to Sapacitabine in Acute Myelogenous LeukemiaDNA damage accumulation and repair defects in acute myeloid leukemia: implications for pathogenesis, disease progression, and chemotherapy resistance.Prognostic impact of white blood cell count in intermediate risk acute myeloid leukemia: relevance of mutated NPM1 and FLT3-ITD.INPP4B-mediated DNA repair pathway confers resistance to chemotherapy in acute myeloid leukemia.NADPH oxidase-generated hydrogen peroxide induces DNA damage in mutant FLT3-expressing leukemia cells.Resistance to FLT3 inhibition in an in vitro model of primary AML cells with a stem cell phenotype in a defined microenvironment.Autonomous magnetic labelling of functional mesenchymal stem cells for improved traceability and spatial control in cell therapy applications.Internal tandem duplication and tyrosine kinase domain mutations in FLT3 alter the response to daunorubicin in Ba/F3 cells.Genomic instability is a principle pathologic feature of FLT3 ITD kinase activity in acute myeloid leukemia leading to clonal evolution and disease progression.DNA damage in acute myeloid leukemia patients of Northern Mexico.Analysis of factors that affect in vitro chemosensitivity of leukaemic stem and progenitor cells to gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukaemia.Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status--consequences and potentials for pharmacological intervention.FLT3-ITD and MLL-PTD influence the expression of MDR-1, MRP-1, and BCRP mRNA but not LRP mRNA assessed with RQ-PCR method in adult acute myeloid leukemia.Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.
P2860
Q28259732-9A0315E1-0B40-4C59-9A65-3F21619606D6Q28289859-D201D79A-233D-4800-9683-024C341E44B8Q28482247-DF406D61-1058-4810-AD37-7036B838FF91Q34421932-4BBED232-F242-454E-B865-EBA6486B10FAQ34450478-99A3F626-4D06-45BD-9525-7FB304C13DB9Q34578418-32FA8AA3-778D-47B9-AEA2-76E36EF8DE7FQ34709391-AEDA8B5D-5D8F-4C9B-B9CE-BEC8D3844AECQ35075792-B4EE60E4-E0C5-4E66-9D49-0134AA087E95Q35784511-8C81E754-2399-4EA0-9296-A7950C65FE06Q35808597-DC6F0540-CFD5-4053-ABB8-EFDE5B931F04Q36835812-5CFE4A12-7AE7-4B2E-B0C8-A0C3E9CC5651Q36978266-7D705A21-1045-4BEB-903D-43AC9DE2F3B7Q37092210-0086532B-7160-46D4-AA4B-6E3CF48ED242Q37100102-7C4D4198-D85E-4522-A437-A4BFF8849592Q38238954-2232297D-4B19-4CBD-AE0B-E24851843670Q38289289-A2AD14A6-7169-407F-84AA-FF265AEEA7EAQ38736981-845F3151-EBA2-4DA7-AFC2-8FAB7CC396B1Q38908003-0DDB969C-A9EC-4561-8CA5-C979B061C0AEQ39977455-C4DB5F8A-3BB0-43B6-8885-B32AE1F484BAQ41540394-28C804C7-88B1-47D3-9DFF-3EE9EBABCCC8Q42177447-271CF67B-92D9-4D30-AEDA-DCFCF160CC74Q46406409-825C688D-CA13-4A4F-9490-C03E812BFB99Q47132650-DA199B00-360C-4364-A0D4-F0529225046DQ53369470-745E6767-A043-41F3-8879-B18DD03623D4Q53769196-4F7EBE7F-EF17-4C13-AFF6-891427284F9EQ54243631-B7B2DE03-2E0E-44E8-9878-1A86A241A62BQ54978631-EF67A8F2-28D9-4E46-A4D7-7EDA1A9AD592
P2860
DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
DNA repair contributes to the ...... by the FLT3 inhibitor PKC412.
@en
type
label
DNA repair contributes to the ...... by the FLT3 inhibitor PKC412.
@en
prefLabel
DNA repair contributes to the ...... by the FLT3 inhibitor PKC412.
@en
P2093
P2860
P356
P1433
P1476
DNA repair contributes to the ...... by the FLT3 inhibitor PKC412.
@en
P2093
A-M Massip
B Lloyd-Lewis
C H Seedhouse
G I Carter
H M Hunter
N H Russell
P2860
P2888
P304
P356
10.1038/SJ.LEU.2404439
P577
2006-10-26T00:00:00Z
P5875
P6179
1026635651